Shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) are set to reverse split before the market opens on Thursday, March 23rd. The 1-40 reverse split was announced on Thursday, March 23rd. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, March 23rd.
RedHill Biopharma Stock Down 24.3 %
RDHL stock opened at $0.14 on Friday. RedHill Biopharma has a 12-month low of $0.13 and a 12-month high of $3.27. The company has a market cap of $13.14 million, a price-to-earnings ratio of -0.09 and a beta of 2.28. The company has a 50 day moving average of $0.20 and a two-hundred day moving average of $0.39.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on shares of RedHill Biopharma in a research report on Thursday. They issued a “hold” rating for the company.
Institutional Investors Weigh In On RedHill Biopharma
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.